DAWES KAREN A
Known title: DirectorCIK: 0001261506
Associated companies
Transaction History
| RGEN | ▲ Buy | Grant | 995 | $0 | 5/14/2026 | View on chart |
| RGEN | ▼ Sell | Open Market | 275 | $44K | 12/17/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 973 | $0 | 5/15/2025 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 2,953 | $200K | 6/14/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 803 | $0 | 5/16/2024 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 4,626 | $195K | 2/27/2024 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,000 | $193K | 2/27/2024 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 7,392 | $134K | 8/29/2023 | View on chart |
| RGEN | ▼ Sell | Open Market | 850 | $146K | 8/29/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 798 | $0 | 5/18/2023 | View on chart |
| RGEN | ▼ Sell | Open Market | 775 | $176K | 9/9/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 644 | $0 | 5/26/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 2,576 | $384K | 5/25/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 7,677 | $1.2M | 5/25/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,845 | $279K | 5/25/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,875 | $285K | 5/25/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 742 | $113K | 5/25/2022 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 4,783 | $125K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 462 | $120K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 236 | $62K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,038 | $272K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,119 | $295K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 336 | $89K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 488 | $129K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 486 | $130K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 349 | $93K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 255 | $69K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 14 | $4K | 11/10/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 64 | $19K | 11/2/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 251 | $76K | 11/2/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 446 | $135K | 11/2/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 532 | $161K | 11/2/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 124 | $38K | 11/2/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 700 | $214K | 11/2/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 283 | $87K | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.